A need for circulating biomarkers of severe persistent asthma and its treatment

Clinical and Experimental Allergy

Volumn 36, Issue 11, 2006, Pages 1355-1356

  Holgate, S T ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 6; INTERLEUKIN 8; OMALIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; EDITORIAL; HUMAN; INFLAMMATION; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOLOGICAL MARKERS; CYTOKINES; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE COUNT; LEUKOTRIENE ANTAGONISTS; NEUTROPHILS; TH1 CELLS; TREATMENT OUTCOME;

EID: 33750568192     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02605.x     Document Type: Editorial

References (17)

1. Accordini S, Bugiani M, Arossa W et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol 2006; 141:189-98.
2. Holgate ST, Holloway J, Wilson S et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117:496-506.
3. Lanier BQ. Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2-year observation of clinical experience. Allergy Asthma Proc 2005; 26:435-9.
4. The ENFUMOSA cross sectional European Multicentre Study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22:470-7.
5. Tonnel AB, Gosset P, Tillie-Leblond I. Characteristics of the Inflammatory response in bronchial lavage fluids from patients with status asthmaticus. Int Arch Allergy Immunol 2001; 124:267-71.
6. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-8.
7. Bacci E, Cianchetti S, Bartoli M et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006; 129:565-72.
8. Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN. Anti-TNF therap: where have we got to in 2005? J Autoimmun 2005; 25 (Suppl.):26-28.
9. Howarth PH, Babu KS, Arshad H et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 2005; 60:1012-8.
10. Shah A, Church MK, Holgate ST. Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy 1995; 25:1038-44.
11. Berry MA, Hargadon B, Shelley M et al. Evidence of a role for TNFalpha in refractory asthma. N Engl J Med 2006; 354:697-708.
12. Waserman S, Dolovich J, Conway M, Marshall JS. TNF-alpha dysregulation in asthma: relationship to ongoing corticosteroid-therapy. Can Respir J 2000; 7:229-37.
13. Erin EM, Leaker BR, Nicholson GC et al. The effects of a monoclonal antibody directed against tumour necrosis factor-alpha (TNF-a) in asthma. Am J Respir Crit Care Med 2006; 174:753-62.
14. Silvestri M, Bontempelli M, Giacomelli M et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation? Clin Exp Allergy 2006; 36:1373-81.
15. Burkart KM, Barton SJ, Holloway JW et al. Association of asthma with a functional promoter polymorphism in the IL16 gene. J Allergy Clin Immunol 2006; 117:86-91.
16. Berry MA, Parker D, Neale N et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004; 114:1106-9.
17. Cazzola M, Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol 2006; 6:43-50.